Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act
Similar Posts
Understanding the Risks of Compounded Drugs
Compounded drugs are not FDA-approved. This means the agency does not verify their safety, effectiveness or quality before they are marketed. Learn more.Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Drug Shortage Mitigation Efforts
The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law on March 27, 2020 to aid response efforts and ease the economic impact of COVID-19.Special Edition Platinum 10K contains hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use Special Edition Platinum 10K, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.Lincare, Inc. dba United Medical Home Infusion, Little Rock, AR. State Referral Letter Issued 03/05/2018
Lincare, Inc. dba United Medical Home Infusion, Little Rock, AR. State Referral Letter Issued 03/05/2018Task Description Request Please post to the 2018 Pharmacy Inspections and Related Records Web page
Record Date 03/05/2018
FEI Number 3011564121
Firm Name Lincare, Inc. dba United MedicalQualified Clinical Outcome Assessments (COA)
The table below lists qualified Clinical Outcome Assessments (COA). The tables include legacy projects (those submitted prior to passage of the 21st Century Cures Act), as well as those submitted as part of the newer section 507 process (referring to section 507 of the Federal Food, Drug and CosmetiSafety Labeling Change Orders
Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(o)(4)) authorizes FDA to require application holders for certain drugs to make labeling changes based on new safety information. Learn more.